Bing

SEARCH HISTORY

Investors in MannKind Corp (Symbol: MNKD) saw new options begin trading today, for the September 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain …
NASDAQ · 7/23/2015
contract
Corey Rosenbloom: A couple readers have asked me to chart MannKind (NASDAQ:MNKD) – a low priced but high volume stock – and indeed shares are facing a key support level here. Let’s pinpoint the current …
ETF Daily News · 7/30/2015
Simple Support
MannKind (NASDAQ:MNKD) traded down 3.81% during mid-day trading on Friday, reaching $4.29. The company had a trading volume of 4,108,707 shares. MannKind has a 12-month low of $3.46 and a 12-month high of $10.08. The stock has a 50 day …
Ticker Report · 12 hours ago
MannKind
More from Bing News
What: MannKind Corp.'s (NASDAQ:MNKD) stock briefly fell by 11% today after its marketing partner Sanofi (NYSE:SNY) reported its second-quarter sales for the inhaled insulin product Afrezza. According to the press release, Afrezza's second-quarter sales ...
The Motley Fool · 7/30/2015
MannKind Corp
We close out with a wide-ranging discussion of the stock's valuation, which, consistent with all of our previous assessments published by Seeking Alpha, strongly suggest that MNKD stock represents a very attractive investment opportunity. Contrary to what ...
Seeking Alpha · 7/23/2015
Afrezza
VALENCIA, Calif. (TheStreet) -- MannKind (MNKD) is using a mix of discounted stock and more debt to settle a $100 million convertible loan coming due in two weeks. The stock-for-debt exchange, which covers a bit …
The Street · ByAdam Feuerstein · 7/29/2015
MannKind
Shares of MannKind (NASDAQ:MNKD) opened at 4.29 on Friday. The company’s 50-day moving average is $5.45 and its 200 day moving average is $5.50. The stock’s market capitalization is $1.72 billion. MannKind has a 52 week low of $3.46 and a 52 …
Mideast Times · 1 day ago
which markets MNKD's Afrezza -- reported disappointing second-quarter sales of the inhaled insulin drug. Today's negative price action just extends Wednesday's sell-off, when the stock surrendered nearly 8% after the …
Schaeffer's Investment Research · 7/30/2015
Synergy Pharmaceuticals Inc
MannKind (NASDAQ:MNKD) is one of today's worst performing low-priced stocks, down 5.8% to $4.54 on 1.2x average daily volume. Thus far today, MannKind has traded 6.3 million shares, vs. average volume of 5.2 million shares per day. The stock has ...
Financial News Network Online · ByPeter Chu · 7/29/2015
Shares Down
MannKind Corporation (NASDAQ:MNKD) stock is primed to take off higher as the much-awaited launch of its inhalable insulin drug, Afrezza, approaches. MNKD stock and its $2.3 billion market capitalization hang in the balance, as its fate could ultimately ...
Investor Place · 1/23/2015